L-arginine-nitric oxide-asymmetric dimethylarginine pathway and the coronary circulation: translation of basic science results to clinical practice
By 1980, it was thought that we already knew most of the major mechanisms regulating
vascular tone. However, after the somewhat serendipity discovery that endothelium is …
vascular tone. However, after the somewhat serendipity discovery that endothelium is …
Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery
R Hall - Journal of Cardiothoracic and Vascular Anesthesia, 2013 - jcvaonline.com
THE SYSTEMIC INFLAMMATORY RESPONSE (man-ifested by pyrexia, leukocytosis,
tachycardia, hypotension, tissue fluid accumulation, and organ failure) is generated during …
tachycardia, hypotension, tissue fluid accumulation, and organ failure) is generated during …
Asymmetric dimethylarginine and oxidative stress following coronary artery bypass grafting: associations with postoperative outcome
D Plicner, P Mazur, J Sadowski… - European Journal of …, 2014 - academic.oup.com
OBJECTIVES Elevated asymmetric dimethylarginine (ADMA) is associated with an
increased risk of coronary artery disease. A prognostic value of ADMA following coronary …
increased risk of coronary artery disease. A prognostic value of ADMA following coronary …
[HTML][HTML] ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
A Kahraman, E Mutlu, M Aldağ - Journal of Medical Biochemistry, 2017 - ncbi.nlm.nih.gov
Background In this study, the effects of olmesartan therapy on asymmetric dimethylarginine
(ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase …
(ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase …
Angiotensin-converting enzyme inhibition improves the effectiveness of transcutaneous carbon dioxide treatment
B Nemeth, I Kiss, T Jencsik, I Peter, Z Kreska… - in vivo, 2017 - iv.iiarjournals.org
Aim: To study the effect of carbon dioxide (CO2) therapy on the nitric oxide (NO) pathway by
monitoring plasma asymmetric dimethylarginine (ADMA) concentrations. Patients and …
monitoring plasma asymmetric dimethylarginine (ADMA) concentrations. Patients and …
Changes in ADMA/DDAH pathway after hepatic ischemia/reperfusion injury in rats: the role of bile
A Ferrigno, V Rizzo, A Bianchi… - BioMed research …, 2014 - Wiley Online Library
We investigated the effects of hepatic ischemia/reperfusion (I/R) injury on asymmetric
dimethylarginine (ADMA, a nitric oxide synthase inhibitor), protein methyltransferase (PRMT) …
dimethylarginine (ADMA, a nitric oxide synthase inhibitor), protein methyltransferase (PRMT) …
Changes in ADMA and TAFI levels after stenting in coronary artery disease patients
NM Khalifa, MZ Gad, AA Hataba… - Molecular Medicine …, 2012 - spandidos-publications.com
The aim of this study was to examine the contribution of asymmetric dimethylarginine
(ADMA), an endogenous inhibitor of nitric oxide synthase (NOS) and a novel marker of …
(ADMA), an endogenous inhibitor of nitric oxide synthase (NOS) and a novel marker of …
Symmetrical dimethylarginine as a biomarker for acute kidney injury
O Tutarel, JT Kielstein - The Annals of thoracic surgery, 2012 - annalsthoracicsurgery.org
1. Sun X, Boyce SW, Hill PC, et al. Association of body mass index with new-onset atrial
fibrillation after coronary artery bypass grafting operations. Ann Thorac Surg 2011; 91: 1852 …
fibrillation after coronary artery bypass grafting operations. Ann Thorac Surg 2011; 91: 1852 …
Asymmetric dimethylarginine: Is it a risk facgtor in the repair of aortic coarctation?
Background Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide
synthase, causes endothelial dysfunction which is an important risk factor for mortality in …
synthase, causes endothelial dysfunction which is an important risk factor for mortality in …
Coronary Artery Bypass Grafting and Biomarkers
Coronary artery bypass grafting (CABG) is regarded as the mainstay of treatment in selected
patients with coronary artery disease including those with left-main, three-vessel disease, or …
patients with coronary artery disease including those with left-main, three-vessel disease, or …